1. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
- Author
-
Gay, Cynthia L, James, Katherine S, Tuyishime, Marina, Falcinelli, Shane D, Joseph, Sarah B, Moeser, Matthew J, Allard, Brigitte, Kirchherr, Jennifer L, Clohosey, Matthew, Raines, Samuel L M, Montefiori, David C, Shen, Xiaoying, Gorelick, Robert J, Gama, Lucio, McDermott, Adrian B, Koup, Richard A, Mascola, John R, Floris-Moore, Michelle, Kuruc, JoAnn D, and Ferrari, Guido
- Subjects
HIV infections ,CLINICAL trial registries ,HIV antibodies ,VIREMIA ,IMMUNOGLOBULINS ,VIRAL physiology ,RESEARCH funding ,T cells ,HIV - Abstract
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell-associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration. NCT03803605. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF